Biotechnology company decoding the dark matter of the human genome
Nucleome Therapeutics has raised €38M across 1 funding round from 5 investors, most recently a Series A round in Oct 2022. Based in Oxford, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-10-19 | Series A | €38M |
| British PatientCapital,Johnson & Johnson Innovation – JJDC,M Ventures,Oxford Science Enterprises,Pfizer Ventures |
| View deal → |
